Class information for:
Level 1: BIOSIMILARS//BIOSIMILAR//ANTI ERYTHROPOIETIN ANTIBODIES

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
12067 870 29.4 63%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
875 10801 ERYTHROPOIETIN//DARBEPOETIN ALFA//ANEMIA

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 BIOSIMILARS Author keyword 46 43% 9% 82
2 BIOSIMILAR Author keyword 38 41% 8% 71
3 ANTI ERYTHROPOIETIN ANTIBODIES Author keyword 19 80% 1% 12
4 SIMILAR BIOTHERAPEUTIC PRODUCTS Author keyword 18 89% 1% 8
5 SUBSEQUENT ENTRY BIOLOGICS Author keyword 15 88% 1% 7
6 PURE RED CELL APLASIA Author keyword 12 18% 7% 58
7 ANTI DRUG ANTIBODY Author keyword 11 47% 2% 17
8 ANTIERYTHROPOIETIN ANTIBODIES Author keyword 9 83% 1% 5
9 EPOETIN ZETA Author keyword 8 70% 1% 7
10 ANTI ERYTHROPOIETIN ANTIBODY Author keyword 8 100% 1% 5

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 BIOSIMILARS 46 43% 9% 82 Search BIOSIMILARS Search BIOSIMILARS
2 BIOSIMILAR 38 41% 8% 71 Search BIOSIMILAR Search BIOSIMILAR
3 ANTI ERYTHROPOIETIN ANTIBODIES 19 80% 1% 12 Search ANTI+ERYTHROPOIETIN+ANTIBODIES Search ANTI+ERYTHROPOIETIN+ANTIBODIES
4 SIMILAR BIOTHERAPEUTIC PRODUCTS 18 89% 1% 8 Search SIMILAR+BIOTHERAPEUTIC+PRODUCTS Search SIMILAR+BIOTHERAPEUTIC+PRODUCTS
5 SUBSEQUENT ENTRY BIOLOGICS 15 88% 1% 7 Search SUBSEQUENT+ENTRY+BIOLOGICS Search SUBSEQUENT+ENTRY+BIOLOGICS
6 PURE RED CELL APLASIA 12 18% 7% 58 Search PURE+RED+CELL+APLASIA Search PURE+RED+CELL+APLASIA
7 ANTI DRUG ANTIBODY 11 47% 2% 17 Search ANTI+DRUG+ANTIBODY Search ANTI+DRUG+ANTIBODY
8 ANTIERYTHROPOIETIN ANTIBODIES 9 83% 1% 5 Search ANTIERYTHROPOIETIN+ANTIBODIES Search ANTIERYTHROPOIETIN+ANTIBODIES
9 EPOETIN ZETA 8 70% 1% 7 Search EPOETIN+ZETA Search EPOETIN+ZETA
10 ANTI ERYTHROPOIETIN ANTIBODY 8 100% 1% 5 Search ANTI+ERYTHROPOIETIN+ANTIBODY Search ANTI+ERYTHROPOIETIN+ANTIBODY

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 BIOTECHNOLOGY PRODUCTS 93 65% 10% 88
2 ANTIERYTHROPOIETIN ANTIBODIES 82 61% 10% 86
3 HOST ANTIBODIES 77 72% 7% 61
4 BIOLOGICAL THERAPEUTICS 24 91% 1% 10
5 INNOVATOR INFLIXIMAB 19 60% 2% 21
6 BIOSIMILARS 18 45% 3% 29
7 RED CELL APLASIA 17 15% 12% 107
8 LIGAND BINDING ASSAYS 15 35% 4% 36
9 THERAPEUTIC PROTEIN PRODUCTS 15 88% 1% 7
10 RISK BASED APPROACH 13 61% 2% 14

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Biosimilar agents in oncology/haematology: from approval to practice 2011 41 11 82%
Traceability of biologicals: present challenges in pharmacovigilance 2015 5 20 25%
Development and Regulation of Biosimilars: Current Status and Future Challenges 2013 13 4 100%
Assessing the bioequivalence of biosimilars The Retacrit (R) case 2009 29 3 100%
The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper 2014 8 24 54%
The role of biosimilars in the treatment of rheumatic diseases 2013 37 26 38%
Pharmacovigilance and biosimilars: considerations, needs and challenges 2013 16 20 75%
Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products 2008 133 18 67%
Biosimilars: how similar? 2014 5 10 70%
Active and passive surveillance of enoxaparin generics: a case study relevant to biosimilars 2015 2 10 40%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 PRECLIN CLIN DEV SCI 4 67% 0.5% 4
2 MARKER LOCALIZAT ASSAYS 4 75% 0.3% 3
3 PHARMACEUT SCI INNOVAT STUDIES 4 75% 0.3% 3
4 THER EUT BIOL ONCOL PROD 4 75% 0.3% 3
5 BIOPHARMA SERV 3 60% 0.3% 3
6 CLIN ASSAY DEV 2 67% 0.2% 2
7 DIPARTIMENTO INTERAZIENDALE NEFROL DIALISI TR 2 67% 0.2% 2
8 LARGE MOL BIOANALYT ASSAY DEV 2 67% 0.2% 2
9 BIOSTAT MED SCI 2 50% 0.3% 3
10 BIOANALYT SCI BIOL 2 43% 0.3% 3

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000132043 PROTEIN FORMULATION//SUBVISIBLE PARTICLES//PROTEIN AGGREGATION
2 0.0000118188 TGN1412//SAFETY PHARMACOLOGY//REPEAT DOSE TOXICITY STUDIES
3 0.0000114758 CARDIOVASC METABOL SERV//FORMULARY DEV//SPECIALTY DRUGS
4 0.0000110814 SISCAPA//PSAQ//BIOMARKER VERIFICATION
5 0.0000109707 ANTI CYTOKINE VACCINATION//ANTI IFN ALPHA IMMUNIZATION//INTERFERON ANTIBODIES
6 0.0000076054 PEGFILGRASTIM//FEBRILE NEUTROPENIA//FILGRASTIM
7 0.0000073570 INTELLECTUAL PROPERTY PROGRAM//CARDIORENAL DRUGS//FOOD DRUG GRP
8 0.0000072039 ERYTHROPOIETIN//DARBEPOETIN ALFA//RENAL ANEMIA
9 0.0000068906 FCRN//NEONATAL FC RECEPTOR//TARGET MEDIATED DRUG DISPOSITION
10 0.0000067026 DRUG SHORTAGES//VACCINE STOCKPILES//VACCINE SHORTAGE